Phosphatidylinositol signaling system (PI signaling system)

The Phosphatidylinositol (PI) signaling system is a complex network of enzymes and second messengers that translate extracellular signals into diverse cellular responses. This system relies on the reversible phosphorylation of the inositol ring of phosphatidylinositol lipids by various kinases (e.g., PI3Ks) and phosphatases (e.g., PTEN), as well as their cleavage by phospholipase C (PLC). These reactions generate critical second messengers like PIP3, IP3, and diacylglycerol (DAG), which regulate downstream effectors such as AKT and Protein Kinase C (KEGG: map04070). Dysregulation of the PI signaling system is a hallmark of numerous pathologies; for instance, hyperactivation of the PI3K-AKT arm is one of the most common drivers in human cancers, while impaired inositol recycling is linked to mood disorders. Therapeutic strategies involve targeting specific nodes within the system, such as isoform-specific PI3K inhibitors for oncology or inositol monophosphatase inhibitors for neuropsychiatric conditions. However, because this system is central to glucose metabolism and broad cellular homeostasis, pharmacological modulation often carries risks of metabolic side effects, such as hyperglycemia (PubMed: 30602035; UniProt: PATH-146).

Other names

Phosphoinositide signaling pathwayInositol phosphate signaling pathwayPI3K-Akt signaling pathwayInositol lipid signaling

Drugs targeting this system generally act as competitive inhibitors of specific enzymatic components. For example, PI3K inhibitors block the phosphorylation of phosphatidylinositol 4,5-bisphosphate (PIP2) into phosphatidylinositol 3,4,5-trisphosphate (PIP3), while drugs like lithium inhibit inositol monophosphatase (IMPase), preventing the recycling of inositol and depleting the cellular pool of phosphoinositides required for signal propagation (StatPearls: Phosphoinositide 3-Kinase; PubMed: 22212135).